Table 1.
Baseline characteristics
| Baseline characteristics | All subjects (N = 338) | Discovery cohort (N = 175) | Replication cohort (N = 163) | AMI (N = 60) | No AMI (N = 278) | P -value |
|---|---|---|---|---|---|---|
| Age (years) |
62 ± 11 |
67 ± 10 |
56 ± 10 |
65 ± 11 |
61 ± 11 |
0.014 |
| Male gender (%) |
218 (65) |
112 (64) |
106 (65) |
47 (78) |
171 (62) |
0.015 |
| Caucasian race (%) |
331 (98) |
170 (97) |
163 (100) |
58 (97) |
273 (99) |
0.19 |
| Systolic blood pressure (mmHg) |
138 ± 23 |
142 ± 23 |
133 ± 21 |
135 ± 23 |
138 ± 23 |
0.36 |
| BMI (kg/m2) |
30 ± 7 |
29 ± 6 |
31 ± 8 |
29.6 ± 6.8 |
30.2 ± 7.0 |
0.53 |
| Serum creatinine (mg/dl) |
1.3 ± 1.1 |
1.3 ± 1.4 |
1.2 ± 0.7 |
1.6 ± 2.2 |
1.2 ± 0.7 |
0.009 |
| Acute MI (%) |
60 (18) |
37 (21) |
23 (14) |
- |
- |
- |
| Old MI (%) |
109 (32) |
61 (35) |
48 (30) |
13 (22) |
96 (35) |
0.060 |
| Current smoking (%) |
73 (22) |
34 (19) |
39 (24) |
8 (14) |
65 (24) |
0.09 |
| Diabetes (%) |
120 (36) |
65 (37) |
55 (34) |
29 (48) |
91 (33) |
0.024 |
| Hypertension (%) |
258 (77) |
142 (81) |
116 (72) |
46 (77) |
212 (77) |
0.98 |
| Dyslipidemia (%) |
263 (78) |
133 (79) |
102 (77) |
47 (78) |
216 (78) |
0.95 |
| Chronic heart failure (%) |
76 (23) |
41 (24) |
35 (21) |
15 (25) |
61 (22) |
0.61 |
| LVEF (%) |
54 ± 11 |
54 ± 11 |
54 ± 11 |
51 ± 11 |
54 ± 11 |
0.06 |
| HDL (mg/dl) |
43 ± 15 |
44 ± 14 |
41 ± 16 |
38 ± 14 |
44 ± 15 |
0.014 |
| LDL (mg/dl) |
92 ± 37 |
91 ± 36 |
94 ± 38 |
85 ± 33 |
94 ± 37 |
0.13 |
| Triglyceride (mg/dl) |
159 ± 115 |
150 ± 93 |
170 ± 137 |
154 ± 107 |
160 ± 117 |
0.73 |
| Total cholesterol (mg/dl) |
166 ± 45 |
164 ± 42 |
169 ± 48 |
153 ± 35 |
169 ± 47 |
0.02 |
| History of CABG (%) |
73 (21) |
42 (24) |
31 (19) |
13 (22) |
60 (22) |
0.99 |
| Gensini score |
35 ± 54 |
38 ± 57 |
31 ± 55 |
48 ± 54 |
32 ± 54 |
0.046 |
| Aspirin use (%) |
83 |
131 (81) |
131 (84) |
48 (89) |
214 (82) |
0.2 |
| Beta blocker use (%) |
213 (67) |
107 (67) |
106 (67) |
45 (82) |
168 (64) |
0.012 |
| Clopidogrel use (%) |
171 (55) |
91 (56) |
80 (53) |
34 (64) |
137 (53) |
0.13 |
| ACE-inh/ARB use (%) |
192 (61) |
100 (62) |
92 (61) |
35 (67) |
157 (60) |
0.35 |
| Statin use (%) |
244 (78) |
129 (80) |
115 (76) |
44 (83) |
200 (77) |
0.33 |
| >50% stenosis (in any major epicardial artery (%) | 235 (70) | 133 (76) | 102 (64) | 59 (93) | 176 (64) | <0.001 |
P-value denotes differences between those with and without AMI. Abbreviations: ACE-inh/ARB angiotensin converting enzyme inhibitor or angiotensin receptor blockers, BMI body mass index, CABG coronary artery bypass graft, HDL high-density lipoprotein, LDL low-density lipoprotein, LVEF left ventricular ejection fraction, MI myocardial infarction.